What is the Impact Factor of Endocrine Metabolic & Immune Disorders-Drug Targets?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Endocrine Metabolic & Immune Disorders-Drug Targets is 2.00, ranking in quartile Q4 of Web of Science (SCIE).

Is Endocrine Metabolic & Immune Disorders-Drug Targets indexed in Web of Science or Scopus?

Yes, Endocrine Metabolic & Immune Disorders-Drug Targets is indexed in Web of Science (SCIE, Q4 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 0.552 (Q3) and an H-index of 69.

Who publishes Endocrine Metabolic & Immune Disorders-Drug Targets and what is the Article Processing Charge (APC)?

Endocrine Metabolic & Immune Disorders-Drug Targets is published by Bentham Science Publishers B.V.. The estimated Article Processing Charge (APC) is approximately $2,930 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Endocrine Metabolic & Immune Disorders-Drug Targets?

The official ISO-4 abbreviation of Endocrine Metabolic & Immune Disorders-Drug Targets is "ENDOCR METAB IMMUNE". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q4Scopus Q3SCImago #10,750Hybrid

Endocrine Metabolic & Immune Disorders-Drug Targets

Abbreviation (ISO):ENDOCR METAB IMMUNE

•

Identifier (ISSN):1871-5303(Print)/2212-3873(Online)

•

Publisher:Bentham Science Publishers B.V.

Official Website Submission Portal Compare

Clarivate IF (2026)

2– 0

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Endocrine Metabolic & Immune Disorders-Drug Targets

WoS Q4

Annual Impact Factor Metric

Current (2026):2

Scopus SJR & RankScopus Q3

0.552

#10,750

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

69 papers with at least that number of citations each

WoS: SCIE / JCRQ4

Self-Citation Rate5%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

237articles/year

17.09% Gold OA•52.27% Original Research

Aims & Scope

Aims & Scope This journal is devoted to timely reviews and original articles of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Moreover, the topics related to effects of food components and/or nutraceuticals on the endocrine-metabolic-immune axis and on microbioma composition are welcome.

Topics Covered (Recognized by AI)

MedicineBiologyInternal MedicineChemistryBiochemistryGeneticsEndocrinologyPathologyImmunologyPsychologyPathology & DiseasesOrganic Chemistry

Primary Research Areas

Endocrinology & Metabolismimmunology Immunology

Official Website NLM PubMed Catalog Submission Portal SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

ENDOCRINOLOGY & METABOLISM

Rank152/198

IndexSCIE

JCRSCIE2026

IMMUNOLOGY

Rank149/183

IndexSCIE

JCRSCIE2026

PHARMACOLOGY & PHARMACY

Rank249/356

IndexSCIE

JCISCIE2026

ENDOCRINOLOGY & METABOLISM

Rank152/198

IndexSCIE

JCISCIE2026

IMMUNOLOGY

Rank144/183

IndexSCIE

JCISCIE2026

PHARMACOLOGY & PHARMACY

Rank266/356

IndexSCIE

Category	Index	Rank	Quartile
ENDOCRINOLOGY & METABOLISM	JCRSCIE	152/198	Q4
IMMUNOLOGY	JCRSCIE	149/183	Q4
PHARMACOLOGY & PHARMACY	JCRSCIE	249/356	Q3
ENDOCRINOLOGY & METABOLISM	JCISCIE	152/198	Q4
IMMUNOLOGY	JCISCIE	144/183	Q4
PHARMACOLOGY & PHARMACY	JCISCIE	266/356	Q3

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF2

Articles / Year162

Total Citations5

2025

IF2

Articles / Year191

Total Citations213

2024

IF2

Articles / Year166

Total Citations526

2023

IF1.9

Articles / Year211

Total Citations1,074

2022

IF2.387

Articles / Year173

Total Citations1,349

Year	Impact Factor	Articles / Year	Total Citations
2026	2	162	5
2025	2	191	213
2024	2	166	526
2023	1.9	211	1,074
2022	2.387	173	1,349
2021	2.895	162	1,460
2020	1.973	290	3,656
2019	1.104	181	3,060
2018	2.013	109	2,077
2017	—	75	1,506
2016	—	32	399
2015	—	48	1,618

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #10,750Scopus Q3SCImago Profile

Scopus Coverage:2006-2026

•

Scopus Broad Areas:Medicine

Scopus Citation Rank (SJR)Q3

0.552

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q3

Citations / Doc (2 years)

2.28

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$2,930 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations1,112

3-Year Documents483

Citable Documents457

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate47.5%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Endocrinology, Diabetes and MetabolismQ3

Immunology and AllergyQ3

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 5%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

4区 (Zone 4)Medicine

Minor Category (Specific Field):

4区ENDOCRINOLOGY & METABOLISM

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Endocrine Metabolic & Immune Disorders-Drug Targets (abbr: ENDOCR METAB IMMUNE, ISSN: 1871-5303) is a peer-reviewed international scholarly journal in the field of ENDOCRINOLOGY & METABOLISMIMMUNOLOGY, published by Bentham Science Publishers B.V. in United Arab Emirates. The periodical holds a Journal Impact Factor (JIF) of 2.00, ranking in quartile Q4 of Web of Science (SCIE), a Scopus SJR indicator of 0.552 (Q3), an H-index of 69.

The journal enforces rigorous peer evaluation with an annual output of approximately 237 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $2,930 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.